Cidara Therapeutics, INC Form 4 insider transactions

Cidara Therapeutics, Inc. Director Bonnie L. Bassler was granted 11,100 stock options with an exercise price of $21.31 per share, vesting on the earlier of June 18, 2026, or the day prior to the company's 2026 annual meeting.

Cidara Therapeutics, Inc. Director Chrysa Mineo acquired additional common stock through open market purchases on June 2 and June 3, 2025, increasing her direct beneficial ownership to 3,320 shares.

Nicole Negar Davarpanah, Chief Medical Officer of Cidara Therapeutics, acquires stock options and restricted stock units (RSUs) as part of compensation.

Cidara Therapeutics CEO Jeffrey Stein was granted 275,000 employee stock options on March 31, 2025, according to a Form 4 filing with the SEC.

Shane Ward, COO & CLO of Cidara Therapeutics, reports the acquisition of 25,000 shares of common stock and 50,000 employee stock options on March 31, 2025.

Shane Ward, COO & CLO of Cidara Therapeutics, reports selling 1,664 shares of common stock to cover tax withholding obligations related to RSU vesting.

Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, sold 1,773 shares of common stock to cover tax withholding obligations related to the vesting and settlement of RSUs.

Frank Karbe, CFO of Cidara Therapeutics, reports the acquisition of common stock and stock options, signaling changes in beneficial ownership.

Director Joshua Resnick acquired 22,200 stock options in Cidara Therapeutics, though he disclaims beneficial ownership due to an arrangement with RA Capital Management.

RA Capital Management and related parties have acquired stock options in Cidara Therapeutics, vesting over a three-year period.

Director Daniel D. Burgess acquired 20,500 stock options in Cidara Therapeutics, Inc. on December 17, 2024.

Director Theodore R. Schroeder acquired 20,500 stock options in Cidara Therapeutics, Inc. on December 17, 2024.

Director Chrysa Mineo acquired 19,000 stock options in Cidara Therapeutics, Inc. on December 17, 2024.

Director Bonnie L. Bassler acquired 16,000 stock options in Cidara Therapeutics, Inc. on December 17, 2024.

A Cidara Therapeutics director, Carin Canale-Theakston, acquired 16,000 stock options on December 17, 2024.

RA Capital Management and related entities have increased their holdings in Cidara Therapeutics through the acquisition of common stock and pre-funded warrants.

Taylor Sandison, Chief Medical Officer of Cidara Therapeutics, acquired stock options on September 30, 2024, according to a Form 4 filing.

Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, acquired stock options on September 30, 2024.

Cidara Therapeutics' CEO, Jeffrey Stein, was granted stock options on September 30, 2024.

Preetam Shah, CFO of Cidara Therapeutics, reports the acquisition of stock options.

Shane Ward, COO & CLO of Cidara Therapeutics, reports the acquisition of stock options.

Chief Medical Officer of Cidara Therapeutics, Taylor Sandison, sold shares to cover tax withholding obligations related to the vesting and settlement of RSUs.

Leslie Tari, Chief Scientific Officer of Cidara Therapeutics, sold 909 shares of common stock to cover tax withholding obligations related to the vesting and settlement of RSUs.

RA Capital Management converted Series A Preferred Stock to common stock in Cidara Therapeutics after the satisfaction of convertibility conditions.

RA Capital Management files an amended Form 4 to correct an error in the reported exercise price of a stock option related to Cidara Therapeutics.

RA Capital Management and related parties report the acquisition of stock options in Cidara Therapeutics, Inc. on July 18, 2024.

Director Daniel D. Burgess acquired 2,125 stock options in Cidara Therapeutics on July 18, 2024.

Director Bonnie L. Bassler acquired stock options in Cidara Therapeutics, Inc. on July 18, 2024.

Director Carin Canale-Theakston acquired stock options in Cidara Therapeutics, Inc. on July 18, 2024.

Director James Merson acquired stock options in Cidara Therapeutics, Inc. on July 18, 2024.